Recent Postings to

Worst Pills, Best Pills Newsletter Articles

  View the entire April 2018 issue in PDF format

  View the entire March 2018 issue in PDF format

  • 10 Rules for Safer Drug Use
    (March 2018)
    Patients often wonder what steps they can take to minimize their chances of suffering a serious adverse drug reaction. This article reviews 10 simple rules developed by Public Citizen’s Health Research Group for ensuring safer drug use.
  • Big Pharma Rings in New Year with More Price Gouging
    (March 2018)
    In his editor’s column, Dr. Michael Carome highlights the most recent wave of price hikes by major pharmaceutical companies at the start of 2018.
  • Review of Gabapentin
    (March 2018)
    The FDA has approved gabapentin (NEURONTIN) for several conditions, including a type of seizure disorder, shingles pain and restless leg syndrome. Hear our recommendations for who should use gabapentin and who should avoid it.
  • FDA: Drug for Treating High Blood Potassium Levels Should Not Be Combined with Other Medications
    (March 2018)
    Last year, the FDA warned that a drug used to treat high blood potassium levels can interfere with the absorption of many other oral medications. Learn the name of this drug and how to take it safely when using other drugs.
  • Questions & Answers
    (March 2018)
    We respond to readers’ questions about our October 2017 article regarding the use of vitamin E for preventing or treating mild cognitive impairment or Alzheimer’s disease and our December 2017 article regarding the use of desmopressin spray (NOCTIVA) for treating nighttime urination symptoms.
  • Meclizine: A Risky and Possibly Ineffective Drug
    (March 2018)
    Meclizine is a drug that is commonly used to treat symptoms of motion sickness. Find out why we have designated this drug as Do Not Use.

  View the entire February 2018 issue in PDF format

  • Do Not Use Fentanyl for Non-Cancer Pain
    (February 2018)
    Fentanyl is a dangerous synthetic opioid that has been involved in an increasing number of overdose deaths in the U.S. Learn why this drug should be used only by cancer patients with breakthrough cancer-related pain.
  • FDA Dragging Its Feet on Improving Presentation of Risk Information in TV Drug Ads
    (February 2018)
    In 2007, Congress passed legislation aimed at improving the disclosure of risk information in TV ads for prescription drugs by mandating that ads present this information in a “clear, conspicuous, and neutral manner.” Worst Pills, Best Pills News Editor Dr. Michael Carome takes the FDA to task for never implementing the requirements of this 2007 law.
  • Incorrect Dosing of Obeticholic Acid (OCALIVA) Could Be Fatal, FDA Warns
    (February 2018)
    Obeticholic acid is a second-line treatment for patients with a rare liver disease called primary biliary cholangitis. In this article, we discuss how to appropriately dose the drug in order to avoid life-threatening liver damage.
  • Clozapine for Treatment-Resistant Schizophrenia: Use With Great Caution
    (February 2018)
    No other schizophrenia medicine is more dangerous than clozapine. Learn about the drug’s serious unique risks and why it should be used only by severely ill schizophrenia patients who have failed to respond adequately to other antipsychotic medications.
  • Drug-Induced Movement Disorders
    (February 2018)
    Abnormal involuntary movements (movement disorders) occur as adverse events associated with many widely used medications and can cause substantial hardship for affected individuals. Find out which drugs are associated with these adverse effects.
  • News Brief for February 2018
    (February 2018)
    In this month’s News Brief, we report on Public Citizen’s Health Research Group’s petition to the FDA to ban a cancer treatment ingredient from use in pharmacy compounding because of serious health risks to humans and no evidence of benefit.
Copyright © 2018 Public Citizen's Health Research Group. All rights reserved.